Chemistry:SDB-005
SDB-005 (also known as NA-PINAC using systematic EUDA nomenclature)[1] is an indazole-based synthetic cannabinoid that has been sold online as a designer drug.[2] It is presumed to be an agonist of the CB1 and CB2 cannabinoid receptors. SDB-005 is the indazole core analog of PB-22 where the 8-hydroxyquinoline has also been replaced with a naphthalene group.
The code number SDB-005 was originally used for a different compound, the N-phenyl instead of N-benzyl analogue of SDB-006. This compound is a potent agonist of the CB1 receptor (Ki = 21 nM) and CB2 receptor (Ki = 140 nM).[3]
However, SDB-005 was subsequently used as the name for the indazole-3-carboxylate compound mentioned above when it was sold in Europe as a designer drug, and was entered into the EMCDDA synthetic drug database under this name.[4] Consequently, there are now two distinct, yet fairly closely related cannabinoid compounds, which may both be referred to under the code SDB-005.
See also
References
- ↑ "EMCDDA framework and practical guidance for naming synthetic cannabinoids". Drug Testing and Analysis 15 (3): 255–276. March 2023. doi:10.1002/dta.3403. PMID 36346325. https://www.euda.europa.eu/drugs-library/emcdda-framework-and-practical-guidance-naming-synthetic-cannabinoids_en.
- ↑ "SDB-005". Cayman Chemical. https://www.caymanchem.com/app/template/Product.vm/catalog/15389.
- ↑ "The synthesis and pharmacological evaluation of adamantane-derived indoles: cannabimimetic drugs of abuse". ACS Chemical Neuroscience 4 (7): 1081–92. July 2013. doi:10.1021/cn400035r. PMID 23551277.
- ↑ EWS_EU: Neue Psychoaktive Substanzen, April 2015
 |  |
